Quantitative systems pharmacology modeling provides insight into inter‐mouse variability of Anti‐CTLA4 response
Abstract Clinical responses of immuno‐oncology therapies are highly variable among patients. Similar response variability has been observed in syngeneic mouse models. Understanding of the variability in the mouse models may shed light on patient variability. Using a murine anti‐CTLA4 antibody as a c...
Main Authors: | Wenlian Qiao, Lin Lin, Carissa Young, Jatin Narula, Fei Hua, Andrew Matteson, Andrea Hooper, Lore Gruenbaum, Alison Betts |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-07-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12800 |
Similar Items
-
Quantitative systems pharmacology model of GITR‐mediated T cell dynamics in tumor microenvironment
by: Yan Ji, et al.
Published: (2023-03-01) -
Engineered ipilimumab variants that bind human and mouse CTLA-4
by: Brett Robison, et al.
Published: (2025-12-01) -
Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework
by: Jessica C. Leete, et al.
Published: (2022-12-01) -
Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
by: Won Jin Ho, et al.
Published: (2022-11-01) -
Correction: Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Published: (2023-01-01)